Clinical Trials Directory

Trials / Completed

CompletedNCT00346827

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Britannia Pharmaceuticals Ltd. · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Conditions

Interventions

TypeNameDescription
DRUGApomorphine Nasal Powder

Timeline

Start date
2006-07-01
Primary completion
2007-08-01
Completion
2007-08-01
First posted
2006-06-30
Last updated
2019-07-10

Source: ClinicalTrials.gov record NCT00346827. Inclusion in this directory is not an endorsement.

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods. (NCT00346827) · Clinical Trials Directory